Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company’s portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue — in the most recent quarter, product revenue climbed in the double digits to nearly $2.8 billion.
My prediction is that Vertex is heading for a once-in-a-generation opportunity, and investors who get in on the stock today should benefit for years to come. Let’s find out more.
This post originally appeared at The Motley Fool.